Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ritalin LA cytogenetic abnormalities study in treatment-naive children with ADHD
2015-004444-19Phase 2
- Sponsor
- Novartis
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of methylphenidate in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Novartis. Primary endpoint: Number of chromosomal aberrations per 100 cells excluding gaps.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on 2015-004444-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004444-19.